Investigating drug-induced mitochondrial toxicity: A biosensor to increase drug safety?

Current Drug Safety

Volumn 4, Issue 1, 2009, Pages 34-54

  Pereira, Cláudia V ^a   Moreira, Ana C ^a   Pereira, Susana P ^a   Machado, Nuno G ^a   Carvalho, Filipa S ^a   Sardão, Vilma A ^a   Oliveira, Paulo J ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Biosensor; Drug safety; High throughput methods; Mitochondria; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; BUPIVACAINE; CARVEDILOL; CISPLATIN; CYCLOPHILIN D; CYCLOSPORIN A; CYTOCHROME P450; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUTAMIDE; GENTAMICIN; GLITAZONE DERIVATIVE; GONADORELIN AGONIST; IDARUBICIN; ISONIAZID; LAMIVUDINE; LIDOCAINE; MITOCHONDRIAL ENZYME; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TAMOXIFEN; VALPROIC ACID; XENOBIOTIC AGENT; ZALCITABINE; ZIDOVUDINE; DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; APOPTOSIS; BIOENERGY; BIOSENSOR; BREAST CANCER; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CARDIOMYOPATHY; CARDIOTOXICITY; DIABETES MELLITUS; DRUG BINDING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ELECTRON TRANSPORT; GRAM NEGATIVE INFECTION; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; LIVER TOXICITY; METHODOLOGY; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL GENETICS; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; NEPHROTOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROSTATE CANCER; RELIABILITY; REVIEW; TUBERCULOSIS; VALIDITY; ANIMAL; DRUG DESIGN; DRUG EFFECT; GENETIC PROCEDURES; METABOLISM; MITOCHONDRION; TOXICITY TESTING;

ANIMALS; BIOSENSING TECHNIQUES; DRUG DESIGN; HUMANS; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; PHARMACEUTICAL PREPARATIONS; TOXICITY TESTS;

EID: 63249131066     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488609787354440     Document Type: Review

References (233)

1. Benard G, Rossignol R. Ultrastructure of the mitochondrion and its bearing on function and bioenergetics. Antioxid Redox Signal 2008; 10(8): 1313-42.
2. Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature 1961; 191: 144-8.
3. Yi M, Weaver D, Hajnoczky G. Control of mitochondrial motility and distribution by the calcium signal: a homeostatic circuit. J Cell Biol 2004; 167(4): 661-72.
4. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86(1): 147-57.
5. Mitchell P, Moyle J. Respiration-driven proton translocation in rat liver mitochondria. Biochem J 1967; 105(3): 1147-62.
6. Kroemer G. Mitochondrial control of apoptosis: an overview. Biochem Soc Symp 1999; 66: 1-15.
7. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000; 92(13): 1042-53.
8. Armstrong JS. Mitochondrial medicine: pharmacological targeting of mitochondria in disease. Br J Pharmacol 2007; 151(8): 1154-65.
9. Dykens JA, Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov Today 2007; 12(17-18): 777-85.
10. Lewis MR, Lewis WH. Mitochondria in tissue culture. Science 1914; 39(1000): 330-3.
11. Bakeeva LE, Chentsov Yu S, Skulachev VP. Mitochondrial framework (reticulum mitochondriale) in rat diaphragm muscle. Biochim Biophys Acta 1978; 501(3): 349-69.
12. Poliakova IA, Zorov DB, Leikina MI. Polarographic study of cell respiration in a tissue culture. Tsitologiia 1983; 25(2): 162-7.
13. Chance B, Williams GR. The respiratory chain and oxidative phosphorylation. Adv Enzymol Relat Subj Biochem 1956; 17: 65-134.
14. Rich PR. The molecular machinery of Keilin's respiratory chain. Biochem Soc Trans 2003; 31(Pt 6): 1095-105.
15. Gilkerson RW, Selker JM, Capaldi RA. The cristal membrane of mitochondria is the principal site of oxidative phosphorylation. FEBS Lett 2003; 546(2-3): 355-8.
16. Bootman MD, Collins TJ, Peppiatt CM, et al. Calcium signalling - an overview. Semin Cell Dev Biol 2001; 12(1): 3-10.
17. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000; 1(1): 11-21.
18. Berridge MJ, Bootman MD, Lipp P. Calcium - a life and death signal. Nature 1998; 395(6703): 645-8.
19. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 2003; 4(7): 552-65.
20. Vasington FD, Murphy JV. Ca ion uptake by rat kidney mitochondria and its dependence on respiration and phosphorylation. J Biol Chem 1962; 237: 2670-7.
21. Giacomello M, Drago I, Pizzo P, Pozzan T. Mitochondrial Ca2+ as a key regulator of cell life and death. Cell Death Differ 2007; 14(7): 1267-74.
22. Crompton M, Heid I. The cycling of calcium, sodium, and protons across the inner membrane of cardiac mitochondria. Eur J Biochem 1978; 91(2): 599-608.
23. Rottenberg H, Marbach M. The Na(+)-independent Ca2+ efflux system in mitochondria is a Ca2+/2H+ exchange system. FEBS Lett 1990; 274(1-2): 65-8.
24. Hajnoczky G, Hager R, Thomas AP. Mitochondria suppress local feedback activation of inositol 1,4, 5-trisphosphate receptors by Ca2+. J Biol Chem 1999; 274(20): 14157-62.
25. Mackenzie L, Roderick HL, Berridge MJ, Conway SJ, Bootman MD. The spatial pattern of atrial cardiomyocyte calcium signalling modulates contraction. J Cell Sci 2004; 117(Pt 26): 6327-37.
26. 2+ within intact uncoupled rat brown adipose tissue mitochondria incubated in the presence and absence of albumin proceedings. Biochem Soc Trans 1980; 8(3): 339.
27. Territo PR, Mootha VK, French SA, Balaban RS. Ca(2+) activation of heart mitochondrial oxidative phosphorylation: role of the F(0)/F(1)-ATPase. Am J Physiol Cell Physiol 2000; 278(2): C423-35.
28. Rizzuto R, Pinton P, Carrington W, et al. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. Science 1998; 280(5370): 1763-6.
29. Altschafl BA, Beutner G, Sharma VK, Sheu SS, Valdivia HH. The mitochondrial ryanodine receptor in rat heart: a pharmaco-kinetic profile. Biochim Biophys Acta 2007; 1768(7): 1784-95.
30. Pinton P, Rizzuto R. Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. Cell Death Differ 2006; 13(8): 1409-18.
31. Ichas F, Mazat JP. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim Biophys Acta 1998; 1366(1-2): 33-50.
32. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2007; 87(1): 99-163.
33. Juhaszova M, Wang S, Zorov DB, et al. The identity and regulation of the mitochondrial permeability transition pore: where the known meets the unknown. Ann N Y Acad Sci 2008; 1123: 197-212.
34. Armstrong JS. The role of the mitochondrial permeability transition in cell death. Mitochondrion 2006; 6(5): 225-34.
35. Scarpa M, Colombo A, Sorgato P, De Renzi E. The incidence of aphasia and global aphasia in left brain-damaged patients. Cortex 1987; 23(2): 331-6.
36. Beutner G, Ruck A, Riede B, Brdiczka D. Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim Biophys Acta 1998; 1368(1): 7-18.
37. Zamzami N, Maisse C, Metivier D, Kroemer G. Measurement of membrane permeability and permeability transition of mitochondria. Methods Cell Biol 2001; 65: 147-58.
38. Galat A, Metcalfe SM. Peptidylproline cis/trans isomerases. Prog Biophys Mol Biol 1995; 63(1): 67-118.
39. Broekemeier KM, Dempsey ME, Pfeiffer DR. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 1989; 264(14): 7826-30.
40. Shimizu S, Matsuoka Y, Shinohara Y, Yoneda Y, Tsujimoto Y. Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. J Cell Biol 2001; 152(2): 237-50.
41. Crompton M, Virji S, Ward JM. Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore. Eur J Biochem 1998; 258(2): 729-35.
42. Crompton M. On the involvement of mitochondrial intermembrane junctional complexes in apoptosis. Curr Med Chem 2003; 10(16): 1473-84.
43. Zamzami N, Marchetti P, Castedo M, et al. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett 1996; 384(1): 53-7.
44. Reed JC, Zha H, Aime-Sempe C, Takayama S, Wang HG. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv Exp Med Biol 1996; 406: 99-112.
45. Yagoda N, von Rechenberg M, Zaganjor E, et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 2007; 447(7146): 864-8.
46. Krauskopf A, Eriksson O, Craigen WJ, Forte MA, Bernardi P. Properties of the permeability transition in VDAC1(-/-) mitochondria. Biochim Biophys Acta 2006; 1757(5-6): 590-5.
47. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, Molkentin JD. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat Cell Biol 2007; 9(5): 550-5.
48. Kokoszka JE, Waymire KG, Levy SE, et al. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 2004; 427(6973): 461-5.
49. Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem 2002; 277(9): 7610-8.
50. Pastorino JG, Hoek JB, Shulga N. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 2005; 65(22): 10545-54.
51. Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005; 434(7033): 658-62.
52. Schinzel AC, Takeuchi O, Huang Z, et al. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci USA 2005; 102(34): 12005-10.
53. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem 2005; 280(19): 18558-61.
54. Tsujimoto Y, Nakagawa T, Shimizu S. Mitochondrial membrane permeability transition and cell death. Biochim Biophys Acta 2006; 1757(9-10): 1297-300.
55. Wieckowski MR, Szabadkai G, Wasilewski M, Pinton P, Duszynski J, Rizzuto R. Overexpression of adenine nucleotide translocase reduces Ca2+ signal transmission between the ER and mitochondria. Biochem Biophys Res Commun 2006; 348(2): 393-9.
56. Miwa S, Brand MD. Mitochondrial matrix reactive oxygen species production is very sensitive to mild uncoupling. Biochem Soc Trans 2003; 31(Pt 6): 1300-1.
57. Choksi KB, Papaconstantinou J. Age-related alterations in oxidatively damaged proteins of mouse heart mitochondrial electron transport chain complexes. Free Radic Biol Med 2008; 44(10): 1795-805.
58. Kowaltowski AJ, Vercesi AE. Mitochondrial damage induced by conditions of oxidative stress. Free Radic Biol Med 1999; 26(3-4): 463-71.
59. Grijalba MT, Vercesi AE, Schreier S. Ca2+-induced increased lipid packing and domain formation in submitochondrial particles. A possible early step in the mechanism of Ca2+-stimulated generation of reactive oxygen species by the respiratory chain. Biochemistry 1999; 38(40): 13279-87.
60. Turrens JF, Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem J 1980; 191(2): 421-7.
61. Muller FL, Liu Y, Abdul-Ghani MA, et al. High rates of superoxide production in skeletal-muscle mitochondria respiring on both complex I- and complex II-linked substrates. Biochem J 2008; 409(2): 491-9.
62. Grivennikova VG, Vinogradov AD. Generation of superoxide by the mitochondrial Complex I. Biochim Biophys Acta 2006; 1757(5-6): 553-61.
63. Han D, Williams E, Cadenas E. Mitochondrial respiratory chain-dependent generation of superoxide anion and its release into the intermembrane space. Biochem J 2001; 353(Pt 2): 411-6.
64. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis 2007; 12(5): 913-22.
65. Meissner C. Mutations of mitochondrial DNA - cause or consequence of the ageing process? Z Gerontol Geriatr 2007; 40(5): 325-33.
66. Pang CY, Ma YS, Wei YU. MtDNA mutations, functional decline and turnover of mitochondria in aging. Front Biosci 2008; 13: 3661-75.
67. Chen Y, Gibson SB. Is mitochondrial generation of reactive oxygen species a trigger for autophagy? Autophagy 2008; 4(2): 246-8.
68. Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ 2008; 15(1): 171-82.
69. Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 2007; 1767(8): 1007-31.
70. Scherz-Shouval R, Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends Cell Biol 2007; 17(9): 422-7.
71. Curtin JF, Donovan M, Cotter TG. Regulation and measurement of oxidative stress in apoptosis. J Immunol Methods 2002; 265(1-2): 49-72.
72. McConkey DJ. Biochemical determinants of apoptosis and necrosis. Toxicol Lett 1998; 99(3): 157-68.
73. Cohen JJ. Programmed cell death in the immune system. Adv Immunol 1991; 50: 55-85.
74. Rai NK, Tripathi K, Sharma D, Shukla VK. Apoptosis: a basic physiologic process in wound healing. Int J Low Extrem Wounds 2005; 4(3): 138-44.
75. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407(6805): 770-6.
76. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256(1): 42-9.
77. Martinou JC, Desagher S, Antonsson B. Cytochrome c release from mitochondria: all or nothing. Nat Cell Biol 2000; 2(3): E41-3.
78. Halestrap AP, Doran E, Gillespie JP, O'Toole A. Mitochondria and cell death. Biochem Soc Trans 2000; 28(2): 170-7.
79. Yang J, Liu X, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275(5303): 1129-32.
80. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6(5): 513-9.
81. Petronilli V, Penzo D, Scorrano L, Bernardi P, Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J Biol Chem 2001; 276(15): 12030-4.
82. Pinton P, Ferrari D, Rapizzi E, Di Virgilio F, Pozzan T, Rizzuto R. The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. Embo J 2001; 20(11): 2690-701.
83. Pinton P, Ferrari D, Rapizzi E, Di Virgilio F, Pozzan T, Rizzuto R. A role for calcium in Bcl-2 action? Biochimie 2002; 84(2-3): 195-201.
84. Biagioli M, Pifferi S, Ragghianti M, Bucci S, Rizzuto R, Pinton P. Endoplasmic reticulum stress and alteration in calcium homeostasis are involved in cadmium-induced apoptosis. Cell Calcium 2008; 43(2): 184-95.
85. Zamzami N, Marchetti P, Castedo M, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995; 181(5): 1661-72.
86. Kelekar A, Thompson CB. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol 1998; 8(8): 324-30.
87. Harris MH, Thompson CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 2000; 7(12): 1182-91.
88. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13(15): 1899-911.
89. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305(5684): 626-9.
90. Lewis W, Kohler JJ, Hosseini SH, et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. Aids 2006; 20(5): 675-84.
91. Lund KC, Wallace KB. Direct, DNA pol-gamma-independent effects of nucleoside reverse transcriptase inhibitors on mitochondrial bioenergetics. Cardiovasc Toxicol 2004; 4(3): 217-28.
92. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res 1994; 74(2): 344-8.
93. Lynx MD, Bentley AT, McKee EE. 3′-Azido-3′-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: a possible mechanism of AZT hepatotoxicity. Biochem Pharmacol 2006; 71(9): 1342-8.
94. Lynx MD, McKee EE. 3′-Azido-3′-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 2006; 72(2): 239-43.
95. de la Asuncion JG, Del Olmo ML, Gomez-Cambronero LG, Sastre J, Pallardo FV, Vina J. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci 2004; 76(1): 47-56.
96. Szabados E, Fischer GM, Toth K, et al. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Radic Biol Med 1999; 26(3-4): 309-17.
97. Valenti D, Barile M, Passarella S. AZT inhibition of the ADP/ATP antiport in isolated rat heart mitochondria. Int J Mol Med 2000; 6(1): 93-6.
98. Lund KC, Wallace KB. Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors. Toxicol Appl Pharmacol 2008; 226(1): 94-106.
99. Amir R, Argoff CE, Bennett GJ, et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 2006; 7(5 Suppl 3): S1-29.
100. Heavner JE. Cardiac toxicity of local anesthetics in the intact isolated heart model: a review. Reg Anesth Pain Med 2002; 27(6): 545-55.
101. Schonfeld P, Sztark F, Slimani M, Dabadie P, Mazat JP. Is bupivacaine a decoupler, a protonophore or a proton-leak-inducer? FEBS Lett 1992; 304(2-3): 273-6.
102. Sztark F, Ouhabi R, Dabadie P, Mazat JP. Effects of the local anesthetic bupivacaine on mitochondrial energy metabolism: change from uncoupling to decoupling depending on the respiration state. Biochem Mol Biol Int 1997; 43(5): 997-1003.
103. Sztark F, Malgat M, Dabadie P, Mazat JP. Comparison of the effects of bupivacaine and ropivacaine on heart cell mitochondrial bioenergetics. Anesthesiology 1998; 88(5): 1340-9.
104. Zhang S, Yao S, Li Q. Effects of ropivacaine and bupivacaine on rabbit myocardial energetic metabolism and mitochondria oxidation. J Huazhong Univ Sci Technol Med Sci 2003; 23(2): 178-9, 83.
105. Sztark F, Nouette-Gaulain K, Malgat M, Dabadie P, Mazat JP. Absence of stereospecific effects of bupivacaine isomers on heart mitochondrial bioenergetics. Anesthesiology 2000; 93(2): 456-62.
106. Jaffe AS. The use of antiarrhythmics in advanced cardiac life support. Ann Emerg Med 1993; 22(2 Pt 2): 307-16.
107. Centini F, Fiore C, Riezzo I, Rossi G, Fineschi V. Suicide due to oral ingestion of lidocaine: a case report and review of the literature. Forensic Sci Int 2007; 171(1): 57-62.
108. Alto LE, Dhalla NS. Effects of some antiarrhythmic agents on dog heart mitochondrial oxidative phosphorylation. Eur J Pharmacol 1979; 59(3-4): 311-4.
109. Chazotte B, Vanderkooi G, Chignell D. Further studies on F1-ATPase inhibition by local anesthetics. Biochim Biophys Acta 1982; 680(3): 310-6.
110. Dzimiri N, Almotrefi AA. Investigation of class I anti-arrhythmic drug actions on guinea-pig cardiac mitochondrial lactate dehydrogenase activity. Clin Exp Pharmacol Physiol 1993; 20(4): 201-6.
111. Tsutsumi Y, Oshita S, Kawano T, et al. Lidocaine and mexiletine inhibit mitochondrial oxidation in rat ventricular myocytes. Anesthesiology 2001; 95(3): 766-70.
112. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Annu Rev Med 2001; 52: 239-57.
113. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49(5): 827-31.
114. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 2001; 56: 239-63.
115. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26(11): 2983-9.
116. Scatena R, Martorana GE, Bottoni P, Giardina B. Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs). IUBMB Life 2004; 56(8): 477-82.
117. Li N, Ragheb K, Lawler G, et al. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 2003; 278(10): 8516-25.
118. Hrdina R, Gersl V, Klimtova I, Simunek T, Machackova J, Adamcova M. Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove) 2000; 43(3): 75-82.
119. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992; 19(5): 529-42.
120. Papkovsky DB. Methods in optical oxygen sensing: protocols and critical analyses. Methods Enzymol 2004; 381: 715-35.
121. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32(2): 302-14.
122. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56(2): 185-229.
123. Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, Matsumoto T. Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci 2002; 70(20): 2377-89.
124. Cassidy SC, Chan DP, Rowland DG, Allen HD. Effects of doxorubicin on diastolic function, contractile reserve, and ventricularvascular coupling in piglets. Pediatr Cardiol 1998; 19(6): 450-7.
125. Serafim TL, Oliveira PJ, Sardao VA, Perkins E, Parke D, Holy J. Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line. Cancer Chemother Pharmacol 2008; 61(6): 1007-18.
126. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197(4299): 165-7.
127. Demant EJ. Inactivation of cytochrome c oxidase activity in mitochondrial membranes during redox cycling of doxorubicin. Biochem Pharmacol 1991; 41(4): 543-52.
128. Palmeira CM, Serrano J, Kuehl DW, Wallace KB. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim Biophys Acta 1997; 1321(2): 101-6.
129. Mimnaugh EG, Trush MA, Bhatnagar M, Gram TE. Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem Pharmacol 1985; 34(6): 847-56.
130. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987; 19(8): 817-28.
131. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43(2): 460-72.
132. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 1997; 100(6): 1501-6.
133. Sardao VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB. Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets. Cell Biol Toxicol 2008.
134. Singal PK, Iliskovic N, Li T, Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997; 11(12): 931-6.
135. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002; 62(16): 4592-8.
136. Oliveira PJ, Wallace KB. Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats - relevance for mitochondrial dysfunction. Toxicology 2006; 220(2-3): 160-8.
137. Solem LE, Heller LJ, Wallace KB. Dose-dependent increase in sensitivity to calcium-induced mitochondrial dysfunction and cardiomyocyte cell injury by doxorubicin. J Mol Cell Cardiol 1996; 28(5): 1023-32.
138. Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res 2001; 61(2): 771-7.
139. Zhou S, Heller LJ, Wallace KB. Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol Appl Pharmacol 2001; 175(1): 60-7.
140. Sokolove PM, Shinaberry RG. Na+-independent release of Ca2+ from rat heart mitochondria. Induction by adriamycin aglycone. Biochem Pharmacol 1988; 37(5): 803-12.
141. Solem LE, Henry TR, Wallace KB. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol Appl Pharmacol 1994; 129(2): 214-22.
142. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 1986; 261(7): 3060-7.
143. Kalyanaraman B, Perez-Reyes E, Mason RP. Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim Biophys Acta 1980; 630(1): 119-30.
144. Nohl H. A novel superoxide radical generator in heart mitochondria. FEBS Lett 1987; 214(2): 269-73.
145. Nohl H, Gille L, Staniek K. The exogenous NADH dehydrogenase of heart mitochondria is the key enzyme responsible for selective cardiotoxicity of anthracyclines. Z Naturforsch [C] 1998; 53(3-4): 279-85.
146. Pineiro-Carrero VM, Pineiro EO. Liver. Pediatrics 2004; 113(4 Suppl): 1097-106.
147. Timmins GS, Deretic V. Mechanisms of action of isoniazid. Mol Microbiol 2006; 62(5): 1220-7.
148. Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 2006; 45(1): 117-26.
149. Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? Crit Care 2005; 9(5): 431-40.
150. Floren LC, Hebert MF, Venook AP, Jordan VC, Cisneros A, Somberg KA. Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction. Ann Oncol 1998; 9(10): 1123-6.
151. Moreira PI, Custodio J, Moreno A, Oliveira CR, Santos MS. Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J Biol Chem 2006; 281(15): 10143-52.
152. Larosche I, Letteron P, Fromenty B, et al. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther 2007; 321(2): 526-35.
153. Nazarewicz RR, Zenebe WJ, Parihar A, et al. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 2007; 67(3): 1282-90.
154. Takashima E, Iguchi K, Usui S, Yamamoto H, Hirano K. Metabolite profiles of flutamide in serum from patients with flutamide-induced hepatic dysfunction. Biol Pharm Bull 2003; 26(10): 1455-60.
155. Fau D, Eugene D, Berson A, et al. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 1994; 269(3): 954-62.
156. Feng JY, Johnson AA, Johnson KA, Anderson KS. Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem 2001; 276(26): 23832-7.
157. Lund KC, Peterson LL, Wallace KB. Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother 2007; 51(7): 2531-9.
158. Redlich G, Zanger UM, Riedmaier S, et al. Distinction between Human Cytochrome P450 (CYP) Isoforms and Identification of New Phosphorylation Sites by Mass Spectrometry. J Proteome Res 2008. (in press)
159. Omura T. Mitochondrial P450s. Chem Biol Interact 2006; 163(1-2): 86-93.
160. Genter MB, Clay CD, Dalton TP, Dong H, Nebert DW, Shertzer HG. Comparison of mouse hepatic mitochondrial versus microsomal cytochromes P450 following TCDD treatment. Biochem Biophys Res Commun 2006; 342(4): 1375-81.
161. Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot-Leclercq MP. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis 2008; 13(1): 11-32.
162. Chen CH, Lin H, Hsu YH, et al. The protective effect of prostacyclin on adriamycin-induced apoptosis in rat renal tubular cells. Eur J Pharmacol 2006; 529(1-3): 8-15.
163. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005; 167(6): 1477-84.
164. Kroning R, Katz D, Lichtenstein AK, Nagami GT. Differential effects of cisplatin in proximal and distal renal tubule epithelial cell lines. Br J Cancer 1999; 79(2): 293-9.
165. Park MS, De Leon M, Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 2002; 13(4): 858-65.
166. Wei Q, Dong G, Franklin J, Dong Z. The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 2007; 72(1): 53-62.
167. Kaushal GP, Kaushal V, Hong X, Shah SV. Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells. Kidney Int 2001; 60(5): 1726-36.
168. Cummings BS, Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 2002; 302(1): 8-17.
169. Baek SM, Kwon CH, Kim JH, Woo JS, Jung JS, Kim YK. Differential roles of hydrogen peroxide and hydroxyl radical in cisplatin-induced cell death in renal proximal tubular epithelial cells. J Lab Clin Med 2003; 142(3): 178-86.
170. Schwerdt G, Freudinger R, Schuster C, Weber F, Thews O, Gekle M. Cisplatin-induced apoptosis is enhanced by hypoxia and by inhibition of mitochondria in renal collecting duct cells. Toxicol Sci 2005; 85(1): 735-42.
171. Cilenti L, Kyriazis GA, Soundarapandian MM, et al. Omi/HtrA2 protease mediates cisplatin-induced cell death in renal cells. Am J Physiol Renal Physiol 2005; 288(2): F371-9.
172. Walker PD, Shah SV. Gentamicin enhanced production of hydrogen peroxide by renal cortical mitochondria. Am J Physiol 1987; 253(4 Pt 1): C495-9.
173. Walker PD, Shah SV. Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J Clin Invest 1988; 81(2): 334-41.
174. Walker PD, Barri Y, Shah SV. Oxidant mechanisms in gentamicin nephrotoxicity. Ren Fail 1999; 21(3-4): 433-42.
175. Servais H, Van Der Smissen P, Thirion G, et al. Gentamicin-induced apoptosis in LLC-PK1 cells: involvement of lysosomes and mitochondria. Toxicol Appl Pharmacol 2005; 206(3): 321-33.
176. Justo P, Lorz C, Sanz A, Egido J, Ortiz A. Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. J Am Soc Nephrol 2003; 14(12): 3072-80.
177. Salducci MD, Chauvet-Monges AM, Tillement JP, et al. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. J Pharmacol Exp Ther 1996; 277(1): 417-22.
178. Simon N, Morin C, Bruguerolle B, Tillement JP. [Effects of trimetazidine on altered functions of rat kidney induced by cyclosporine]. Therapie 2001; 56(5): 583-7.
179. Jeon SH, Piao YJ, Choi KJ, et al. Prednisolone suppresses cyclosporin A-induced apoptosis but not cell cycle arrest in MDCK cells. Arch Biochem Biophys 2005; 435(2): 382-92.
180. Khan HM, Cutkomp LK. Effects of DDT, DDE, and PCBs on mitochondrial respiration. Bull Environ Contam Toxicol 1982; 29(5): 577-85.
181. Masini A, Ceccarelli-Stanzani D, Muscatello U. The effect of oligomycin on rat liver mitochondria respiring in state 4. FEBS Lett 1983; 160(1-2): 137-40.
182. Blondin GA, Knobeloch LM, Read HW, Harkin JM. Mammalian mitochondria as in vitro monitors of water quality. Bull Environ Contam Toxicol 1987; 38(3): 467-74.
183. Ogata M, Mori T, Izushi F, Etoh K, Sakai R, Meguro T, et al. Classification of potentially toxic chemicals based on their effects on mitochondrial respiration. Physiol Chem Phys Med NMR 1983; 15(3): 229-32.
184. Pisani DE, Elliott AJ, Hinman DR, Aaronson LM, Pardini RS. Relationship between inhibition of mitochondrial respiration by naphthoquinones, their antitumor activity, and their redox potential. Biochem Pharmacol 1986; 35(21): 3791-8.
185. Kamo N, Muratsugu M, Hongoh R, Kobatake Y. Membrane potential of mitochondria measured with an electrode sensitive to tetraphenyl phosphonium and relationship between proton electrochemical potential and phosphorylation potential in steady state. J Membr Biol 1979; 49(2): 105-21.
186. Gnaiger E, Lassnig B, Kuznetsov AV, Margreiter R. Mitochondrial respiration in the low oxygen environment of the cell. Effect of ADP on oxygen kinetics. Biochim Biophys Acta 1998; 1365(1-2): 249-54.
187. Gnaiger E. Oxygen conformance of cellular respiration. A perspective of mitochondrial physiology. Adv Exp Med Biol 2003; 543: 39-55.
188. Lemasters JJ. The ATP-to-oxygen stoichiometries of oxidative phosphorylation by rat liver mitochondria. An analysis of ADP-induced oxygen jumps by linear nonequilibrium thermodynamics. J Biol Chem 1984; 259(21): 13123-30.
189. Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y. Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol Sci 2007; 97(2): 539-47.
190. Hynes J, Marroquin LD, Ogurtsov VI, et al. Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicol Sci 2006; 92(1): 186-200.
191. Scaduto RC, Jr., Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 1999; 76(1 Pt 1): 469-77.
192. Etter EF, Kuhn MA, Fay FS. Detection of changes in near-membrane Ca2+ concentration using a novel membrane-associated Ca2+ indicator. J Biol Chem 1994; 269(13): 10141-9.
193. Gerasimenko O, Tepikin A. How to measure Ca2+ in cellular organelles? Cell Calcium 2005; 38(3-4): 201-11.
194. Vanden Berghe P. Fluorescent molecules as tools to study Ca2+ signaling, mitochondrial dynamics and synaptic function in enteric neurons. Verh K Acad Geneeskd Belg 2004; 66(5-6): 407-25.
195. Madeira VM. A rapid and ultrasensitive method to measure Ca++ movements across biological membranes. Biochem Biophys Res Commun 1975; 64(3): 870-6.
196. Lehninger AL. Water uptake and extrusion by mitochondria in relation to oxidative phosphorylation. Physiol Rev 1962; 42: 467-517.
197. Neubert D, Foster GV, Lehninger AL. Effect of temperature on uptake and extrusion of water by isolated rat-liver mitochondria. Biochim Biophys Acta 1962; 60: 492-8.
198. Tedeschi H, Harris DL. Some observations on the photometric estimation of mitochondrial volume. Biochim Biophys Acta 1958; 28(2): 392-402.
199. Garlid KD, Paucek P. Mitochondrial potassium transport: the K(+) cycle. Biochim Biophys Acta 2003; 1606(1-3): 23-41.
200. Das M, Parker JE, Halestrap AP. Matrix volume measurements challenge the existence of diazoxide/glibencamide-sensitive KATP channels in rat mitochondria. J Physiol 2003; 547(Pt 3): 893-902.
201. Lyamzaev KG, Izyumov DS, Avetisyan AV, Yang F, Pletjushkina OY, Chernyak BV. Inhibition of mitochondrial bioenergetics: the effects on structure of mitochondria in the cell and on apoptosis. Acta Biochim Pol 2004; 51(2): 553-62.
202. Okamoto K, Shaw JM. Mitochondrial morphology and dynamics in yeast and multicellular eukaryotes. Annu Rev Genet 2005; 39: 503-36.
203. Poppe M, Reimertz C, Dussmann H, et al. Dissipation of potassium and proton gradients inhibits mitochondrial hyperpolarization and cytochrome c release during neural apoptosis. J Neurosci 2001; 21(13): 4551-63.
204. Rintoul GL, Filiano AJ, Brocard JB, Kress GJ, Reynolds IJ. Glutamate decreases mitochondrial size and movement in primary forebrain neurons. J Neurosci 2003; 23(21): 7881-8.
205. Gao W, Pu Y, Luo KQ, Chang DC. Temporal relationship between cytochrome c release and mitochondrial swelling during UV-induced apoptosis in living HeLa cells. J Cell Sci 2001; 114(Pt 15): 2855-62.
206. Kahlert S, Reiser G. Swelling of mitochondria in cultured rat hippocampal astrocytes is induced by high cytosolic Ca(2+) load, but not by mitochondrial depolarization. FEBS Lett 2002; 529(2-3): 351-5.
207. Schoonen WG, de Roos JA, Westerink WM, Debiton E. Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol In Vitro 2005; 19(4): 491-503.
208. Ludovico P, Sansonetty F, Corte-Real M. Assessment of mitochondrial membrane potential in yeast cell populations by flow cytometry. Microbiology 2001; 147(Pt 12): 3335-43.
209. Aiuchi T, Matsunaga M, Nakaya K, Nakamura Y. Calculation of membrane potential in synaptosomes with use of a lipophilic cation (tetraphenylphosphonium). Chem Pharm Bull (Tokyo) 1989; 37(12): 3333-7.
210. Pereira-da-Silva L, Sherman M, Lundin M, Baltscheffsky H. Inorganic pyrophosphate gives a membrane potential in yeast mitochondria, as measured with the permeant cation tetraphenylphosphonium. Arch Biochem Biophys 1993; 304(2): 310-3.
211. Knobeloch LM, Blondin GA, Read HW, Harkin JM. Assessment of chemical toxicity using mammalian mitochondrial electron transport particles. Arch Environ Contam Toxicol 1990; 19(6): 828-35.
212. Haubenstricker ME, Holodnick SE, Mancy KH, Brabec MJ. Rapid toxicity testing based on mitochondrial respiratory activity. Bull Environ Contam Toxicol 1990; 44(5): 675-80.
213. Bragadin M, Dell'Antone P. A new in vitro toxicity test based on the response to toxic substances in solutions of mitochondria from beef heart. Arch Environ Contam Toxicol 1994; 27(3): 410-4.
214. Brunmair B, Staniek K, Gras F, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004; 53(4): 1052-9.
215. Pereira CV, Machado NG, Oliveira PJ. Mechanisms of Berberine [Natural Yellow 18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-benzodioxolo (5,6-a) quinolizinium]-induced Mitochondrial Dysfunction: Interaction with the Adenine Nucleotide Translocator. Toxicol Sci 2008.
216. Pereira GC, Branco AF, Matos JA, et al. Mitochondrially targeted effects of berberine [Natural Yellow 18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-benzodioxolo(5,6-a) quinolizinium] on K1735-M2 mouse melanoma cells: comparison with direct effects on isolated mitochondrial fractions. J Pharmacol Exp Ther 2007; 323(2): 636-49.
217. Murray J, Schilling B, Row RH, et al. Small-scale immunopurification of cytochrome c oxidase for a high-throughput multiplexing analysis of enzyme activity and amount. Biotechnol Appl Biochem 2007; 48(Pt 4): 167-78.
218. Nadanaciva S, Bernal A, Aggeler R, Capaldi R, Will Y. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol In Vitro 2007; 21(5): 902-11.
219. Dykens JA, Stout AK. Assessment of mitochondrial membrane potential in situ using single potentiometric dyes and a novel fluorescence resonance energy transfer technique. Methods Cell Biol 2001; 65: 285-309.
220. Papkovsky DB, Hynes J, Will Y. Respirometric Screening Technology for ADME-Tox studies. Expert Opin Drug Metab Toxicol 2006; 2(2): 313-23.
221. Ashley N, Adams S, Slama A, et al. Defects in maintenance of mitochondrial DNA are associated with intramitochondrial nucleotide imbalances. Hum Mol Genet 2007; 16(12): 1400-11.
222. Nagiec EE, Wu L, Swaney SM, et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother 2005; 49(9): 3896-902.
223. Blattner JR, He L, Lemasters JJ. Screening assays for the mitochondrial permeability transition using a fluorescence multiwell plate reader. Anal Biochem 2001; 295(2): 220-6.
224. Habib GM, Shi ZZ, Ou CN, Kala G, Kala SV, Lieberman MW. Altered gene expression in the liver of gamma-glutamyl transpeptidase-deficient mice. Hepatology 2000; 32(3): 556-62.
225. Soloman R, Gabizon AA. Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin. Clin Lymphoma Myeloma 2008; 8(1): 21-32.
226. Oliveira PJ, Bjork JA, Santos MS, et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 2004; 200(2): 159-68.
227. Aranda-Michel J, Koehler A, Bejarano PA, et al. Nefazodone-induced liver failure: report of three cases. Ann Intern Med 1999; 130(4 Pt 1): 285-8.
228. Lucena MI, Carvajal A, Andrade RJ, Velasco A. Antidepressant-induced hepatotoxicity. Expert Opin Drug Saf 2003; 2(3): 249-62.
229. Dykens JA, Jamieson JD, Marroquin LD, et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 2008; 103(2): 335-45.
230. Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 2008.
231. Will Y, Dykens JA, Nadanaciva S, et al. Effect of the multi-targeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci 2008; 106(1): 153-61.
232. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 2007; 223(3): 277-87.
233. Liguori MJ, Anderson MG, Bukofzer S, et al. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology 2005; 41(1): 177-86.